title: [Clinical significance of c-myc oncogene amplification in primary hepatocellular carcinoma by interphase fluorescence in situ hybridization].
abstract: OBJECTIVE
  To investigate the relationships between c-myc oncogene amplification in primary hepatocellular carcinoma (HCC) and its clinical prognosis.
  
  
  METHODS
  To detect c-myc oncogene amplification in 100 cases with primary HCC and in 6 cases with satellite nodes by interphase fluorescence in situ hybridization (FISH).
  
  
  RESULTS
  c-myc amplification was detected in 92 of 100 (92%) cases with HCC, 37 of which (37%) showed high copy amplification (HC), 55 (55%) low copy amplification (LC) and 8 (8%) single copy or no amplification (SC). There wasn't statistically different significance between the frequency of c-myc amplification and clinical stage and tumor size, and pathological types (P > 0.05), however, in the 90 follow-up resected cases, the one-year rates of recurrence in HC, LC and SC were 70.6% (24/34), 39.6% (19/48) and 12.5% (1/8) respectively (P < 0.05) but the recurrence rates after more than one year were 14.70% (5/34), 14.6% (7/48) and 0 (0/8) respectively (P > 0.05). Meanwhile, two-year survival rate of patients with HC was significantly lower in comparison with those with LC and SC (P = 0.001).
  
  
  CONCLUSIONS
  There is a high frequency of c-myc oncogene amplification in primary HCC and the fact that the patients with HC showed poorer prognosis indicates that the level of c-myc oncogene amplification may be a sensitive index in the prognosis of HCC.
authors.affiliation: Department of Etiology, Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Fang
authors.forename: B
authors.initials: B
authors.lastname: Huang
authors.forename: Q
authors.initials: Q
authors.lastname: Liang
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.forename: C
authors.initials: C
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000473:pathology; D005260:Female; D005784:Gene Amplification; D016259:Genes, myc / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008113:Liver Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis